HCA Healthcare (HCA) Q2 2020 Earnings Call Transcript

HCA Healthcare (HCA -2.79%)
Q2 2020 Earnings Call
Jul 22, 2020, 9:00 a.m. ET

Contents:

• Prepared Remarks
• Questions and Answers
• Call Participants

Prepared Remarks:

Operator

Welcome to the HCA Healthcare second-quarter 2020 earnings conference call. Today's call is being recorded. [Operator instructions] At this time, for opening remarks and introductions, I would like to turn the call over to vice president of Investor Relations, Mr. Mark Kimbrough.

Please go ahead, sir.

Mark Kimbrough -- Vice President of Investor Relations

Thank you, Ian, and good morning, and welcome to everyone on today's call and our webcast. With me this morning is our CEO, Sam Hazen; and CFO Bill Rutherford; as well as Dr. Jon Perlin, our chief medical officer. Sam and Bill will provide comments on the company's second-quarter results, and then we'll open up for questions.

Before I turn the call over to Sam, let me remind everyone that should today's call contain any forward-looking statements, they're based on management's current expectations. Numerous risks, uncertainties and other factors may cause actual results to differ materially from those that might be expressed today. More information on forward-looking statements and these factors are listed in today's press release and in our various SEC filings. On this morning's call, we may reference measures such as adjusted EBITDA and net income attributable to HCA Healthcare, Inc., excluding losses or gains on sales of facilities, which are non-GAAP financial measures.

A table providing supplemental information on adjusted EBITDA and reconciling the net income attributable to HCA Healthcare, Inc. to adjusted EBITDA is included in today's second-quarter earnings release. This morning's call is being recorded, and a replay of the call will be available later today. I will now turn the call over to Sam.

Sam Hazen -- Chief Executive Officer

Good morning, and thank you for joining today's call. The second quarter was a remarkable 91 days for the company, possibly the most remarkable I have experienced in my 37 years with the organization. It started with a level of uncertainty and uneasiness that was very high as the pandemic began. The middle part was filled with example after example of people inside our company stepping up and delivering for each other and delivering for our patients, all the while strengthening our culture of taking care of others in the right way whenever we are needed.

And finally, it ended with the prowess of our teams on display, showing their abilities to manage relationships with their employees, respond to the needs of their physicians, deliver on operational adjustments that were necessary given the circumstances and build clinical capabilities that not only give us more confidence in responding effectively to the ongoing challenges and resurgence of this pandemic but provide us capabilities to improve our services and create even more value in the future. I have never been more proud to work with this company than I am now. As a shareholder, I hope you are equally as proud to be associated with HCA Healthcare. From day one, we addressed the pandemic with two clear objectives.

The first was to protect our people, that is keep them safe and keep them employed, giving them the assurances they needed, both at work and at home. The second was to protect the company, and that is protect its financial position, so we can continue to serve our communities for years to come. Both of these objectives endure today. And directed by the guiding principles we laid out at the beginning of the pandemic, they allow us to provide the care patients deserve.

Thus far, we have been able to achieve these foundational objectives because of the partnership and hard work of our 280,000 colleagues and 45,000 physicians. I want to thank them for their unwavering commitment and tremendous sacrifices in the midst of this global health crisis. In addition, thorough planning, solid execution, appropriate resource allocation and focused leadership all contributed to numerous positive outcomes. We also had strong collaboration with our partners, health plans, lab companies, suppliers, post-acute providers and others who I also want to thank.

Every quarter of this organization has come together to do what's right. In times of great uncertainty, our people continue to show up and pursue the path forward. We press on in that journey now. In pursuit of the first objective, we implemented a number of pandemic pay programs to support our colleagues, including a program that continued income for them that otherwise would have ceased due to stay-at-home orders and reduced patient volumes.

145,000 colleagues benefited from these programs at a cost to the company of approximately $110 million. As a result, and I'm proud of this fact, not one employee in HCA Healthcare has been laid off or furloughed due to the pandemic. The HCA Hope Fund raised $4.5 million during the quarter, an unprecedented level of contributions from employees, our board and the Frist Foundation. This year, the fund has provided almost $2 million in grants to employees who needed emergency support.

Our mission is to care for and improve human life, which primarily revolves around our patients, but it also revolves around our employees. Truly, we care like family. To date, HCA Healthcare has taken care of more than 33,000 COVID-19 inpatients, including over 5,000 patients who are currently in-house. Throughout this pandemic, we have developed more enterprise capabilities to respond to this crisis, giving us greater confidence as we address the resurgence and the many challenges that exist in the communities that we serve.

Examples of these capabilities include enhanced clinical management protocols for patients on ventilators, increased lab testing capacity and improved turnaround times for results. Currently, 90% of COVID-19 lab results are produced in less than 48 hours, more sophisticated supply chain systems and logistics management. We have distributed over 20 million pieces of personal protective equipment to caregivers. Additionally, we rapidly developed and deployed applications that manage capacity and case management requirements; increased telemedicine product offerings and capacity.

We performed over 500,000 telemedicine visits in the quarter, which was well above prior levels. And finally, we initiated various clinical research projects that should improve patient care in the future. Now let me transition to the earnings report. Like the first quarter, our business was significantly limited by governmental policies that restricted elective procedures in required communities to shelter at home.

As many of our markets begin to reopen in May, patient volumes improved as our teams executed their reboot plans. Over the course of successive two-week periods, we saw sequential improvements in most categories, ending the quarter with modest growth in admissions. For the quarter, admissions were down almost 13%. April was down 27%.

May was down 12%, and June was up 1%. Outpatient volumes across most categories also improved sequentially during the quarter, but we did not reach last year's level for any service. Emergency room visits and outpatient surgeries were each down 33% in the quarter. On the revenue side, the qualitative aspects of our inpatient [Audio gap] specifically, the following two factors drove a 10% increase year over year in inpatient revenue per admission.

First, the overall acuity was higher with case mix index growing 3%; and second, payer mix was better with commercial business representing 28% of admissions as compared to 26% last year. As a result, inpatient revenue was only down around 4%. Outpatient revenue declined 30%. And in total, revenue decreased 12% as compared to the second quarter last year.

The improvement in our financial results was generally better and broader than we expected, but we believe it is too early for us to make any conclusive statements about the future or provide any guidance for the rest of the year. As we manage the company through these remarkable times, we are mindful of our mission, as well as the many uncertainties that remain with respect to the broader recovery of the economy, uninsured levels, government regulations, state budgets and the resurgence and duration of COVID-19. In my comments last quarter, I spoke about the three-stage cost-reduction plan we developed to respond to the different scenarios we had modeled. During the second quarter, we implemented first-stage items and also many second-stage items.

Our teams did a masterful job in executing these plans. In the quarter, salaries and benefits, supplies and other operating expenses collectively declined approximately 11% as compared to the prior year. For the quarter, we recorded pre-tax government stimulus income from the CARES Act of $822 million, which reduced expenses further and increased diluted earnings per share by $1.73. In sum, our overall performance was better than we expected with diluted earnings per share of $3.16, an increase of 46% as compared to the second quarter last year.

We continue to maintain a close watch on the macroeconomic factors that influence our business. Again, as we get further into the year and gain a greater visibility into these factors and the performance of the company, we hope to be in a better position to evaluate the capital and operational decisions that we made earlier in the pandemic. Currently, we are dealing with the resurgence of COVID-19 in many of our communities, in particular Texas and Florida. We made the decision across both states to restrict elective procedures, where appropriate, freeing up capacity and staffing while preserving PPE.

We continue to work with state and local governments to coordinate communitywide efforts. Thus far, we have been able to manage the situation and also provide nonelective care to non-COVID patients who need it. I mentioned in my comments last quarter that I had faith in our team's abilities to adjust their operations, and I believe they would once again respond to this challenge and deliver results. As you can see, they did it again.

We are fortunate to have can-do teams. I'm confident they will continue to deliver for all of our stakeholders. Even though the second quarter felt a lot longer to me than 91 days, I'm reminded once again what an incredible and resilient organization we have, one that is driven by a common purpose to do the right thing for others. As I've highlighted today, we accomplished a lot during this time across multiple dimensions of our business.

These accomplishments, I believe, will position us well for long-term success and continue the great legacy that is HCA Healthcare. Now let me turn the call over to Bill Rutherford for more details on our financial results.

Bill Rutherford -- Chief Financial Officer

OK, thank you, Sam, and good morning, everyone. Let me provide some additional information on the quarter. As we expected, the second quarter saw a progressive improvement each month of the quarter as we evolved from the initial response phase early in the quarter and then entered the reboot phase during the second half of the quarter. We saw improvement from the middle of April, which was our low volume point throughout the quarter in most every volume statistic.

Our same facility admissions declined 12.8% in the quarter compared to the prior-year period, and the monthly progression that Sam mentioned in his comments on admissions occurred with most of our key volume indicators. Same facility inpatient surgeries declined 15.7% in the quarter with April declining about 38%. May was down 12%, and June was up 3% over the prior year. Same facility hospital-based outpatient surgeries were down about 27% in the quarter with April down about 65%, May down about 19%, and June was up 4% from the prior year.

Our outpatient surgeries in our ambulatory surgery centers were down about 40% in the quarter with April down 85%, May down 32%, and June was up 1% over the prior year. Our teams did an incredible job of managing our cost structure during this period of significant volume and revenue fluctuation during the quarter. We began adjusting most of our discretionary and variable expenses in late March and April when the volume declines were most pronounced. We were able to sustain many of the expense improvements throughout the quarter as the volumes began to improve in May and June.

As reflected in our financial statements, our reported revenues declined about $1.5 billion or 12.2% in the quarter from the prior-year period. Our salaries and benefits, supplies and other operating expenses collectively declined approximately $1.1 billion or 10.5% during the quarter compared to the prior year. This is a testament to our management teams across the company and highlights our ability to adequately adjust to the sudden volume declines, as well as efficiently serve the increased volumes we saw during the reboot phase. Let me highlight a couple of other important items in the quarter, starting with the CARES Act.

As we discussed last quarter, the company is very appreciative of the government's recognition of the significant impact this pandemic has had on healthcare providers across the country. As I alluded to previously, our revenue was significantly impacted during the quarter due to this pandemic and the subsequent stopping of most elective procedures. In addition, we experienced significant cost in the preparation and response phase, including our pandemic pay program, other employee assistance efforts, as well as securing adequate supply chain items. We believe the CARES Act funding was developed to account for this volume disruption and to offset some of these costs, both of which began impacting us in the first quarter, and to ensure healthcare providers across the country to continue to offer critical services to the communities they serve.

As noted in our release and financial statements, we recognized $822 million of government stimulus income from the CARES Act during the quarter. This equates to about $590 million on an after-tax basis. As of June 30, we had received approximately $1.4 billion of CARES Act stimulus funding. This included about $920 million from the general distribution and about $450 million from certain targeted distributions for rural and safety net hospitals, as well as hotspot funding.

We have not recognized any of the targeted distributions in our P&L as of June 30 as we are still performing the required analysis and attestation process. The evaluation period and guidance related to the relief fund continue to evolve. And as a result, we recognized $822 million of the $920 million in general distribution funds received in the quarter. Subsequent to June 30, we have received approximately $300 million in additional targeted distribution funds.

Before I conclude, let me speak briefly to some cash flow, balance sheet and liquidity metrics. As we mentioned in our first-quarter call, the company took a number of measures early in this pandemic cycle, including entering into a $2 billion short-term credit facility, suspending our share repurchase program and quarterly dividend, as well as reducing planned capital expenditures. These were in addition to a number of operational adjustments we mentioned earlier. All of these efforts have enhanced the company's liquidity and capability to manage through these uncertain times.

As of June 30, 2020, the company had $7.7 billion of capacity under our credit facilities and $4.6 billion of cash on the balance sheet. Our debt-to-EBITDA leverage was 2.7x as of June 30, 2020, after netting out our cash on the balance sheet. Cash flow from operations was $8.72 billion for the quarter, which includes the following components. We received approximately $4.4 billion in advanced Medicare payments during the quarter.

These amounts are scheduled to be repaid over an eight-month period beginning in August of 2020. The cash flow from operations was also favorably impacted by the approximate $1.4 billion of CARES Act funding received during the quarter I mentioned earlier, as well as the deferral of estimated income tax payments to the third quarter of approximately $200 million and payroll tax deferrals that will be paid in late 2021 and 2022 of approximately $200 million. As we mentioned in our first-quarter call, we have reduced the company's planned capital expenditures. At this point, we anticipate reducing our capital spending to approximately $2.8 billion to $3 billion for 2020 as compared to our original plan of approximately $4.2 billion for the year.

This remains subject to further evaluation of operating trends and opportunities. In short, we believe the steps that we implemented have enhanced the company's financial flexibility as we navigate these unprecedented times. We continue to believe the strength, scale and resiliency of HCA are long-standing and critical attributes that served us well not only during this past quarter but will continue to serve us as we go through the future cycles of this pandemic. So with that, let me turn the call over to Mark, and we'll open it up for Q&A.

Mark Kimbrough -- Vice President of Investor Relations

OK. Well, thank you, Bill. We will now start the question-and-answer session. Ian, would you please give instructions to those who would like to get into the queue?

Questions & Answers:

Operator

[Operator instructions] Your first question comes from the line of Justin Lake of Wolfe Research. Your line is open.

Justin Lake -- Wolfe Research -- Analyst

Thanks. Good morning. Wanted to ask about decremental margins and what you're seeing in COVID-affected cases going late June and mid-July. So appreciate all the color.

The decremental margins were incredibly strong this quarter. I think they're only down about 30% -- near or about 30%. Just curious if that's something that you think is sustainable going forward. And then, can you give us some color on what's happening in Florida and Texas, even in late June, mid of July in terms of volume and payer mix as we've seen a pickup in COVID cases there.

Thanks.

Mark Kimbrough -- Vice President of Investor Relations

All right. Thank you, Justin.

Bill Rutherford -- Chief Financial Officer

Hey, good morning, Justin. So let me start, and I'll ask Sam to add in. So as we mentioned, I think the acuity of the patients that return were higher than they were pre-pandemic. As we saw some of our-higher acuity patients in cardiology, there were scientists and orthopedics return, and the lower-acuity patients were maybe the ones that will take a little bit longer to return.

In addition, we had favorable kind of ICU and NICU days. There was a hype that contributed to the acuity, and so I do think that the margin generation of those higher-acuity patients as they return were higher than normal and what they were prep-pandemic. As we mentioned throughout our prepared remarks, we're very pleased with the response of our operating teams and the efforts we're able to make around discretionary costs and managing the variable costs, and we're very pleased with how we finished the quarter on that. Sam, do you want to give him comments on volume going forward?

Sam Hazen -- Chief Executive Officer

Well, let me speak to Texas and Florida. Those are the two states where we have seen COVID-19 resurgence at its greatest level. We have other components of our company where we are seeing COVID volumes, but they're not to the level that we had seen in Texas and are seeing in Florida. In Texas, which was a little bit ahead of Florida, if you will, with respect to the resurgence, I think the company has done an incredible job at responding to the needs of our communities as have our competitors.

And I think it's a testament to the healthcare system in the country and its ability to respond to these challenges from one place to the other. What we've seen in Texas is that our volumes for COVID patients have peaked and actually started to decline. Whereas in Florida, we've seen a flattening out in a very modest growth rate over the last week, and we hope Florida is maybe a week behind what's going on inside of Texas. In total, our activity levels are up slightly in July as compared to June with respect to overall inpatient census.

Clearly, with our decision to restrict elective care to manage our response to the community, we have seen slowdown in surgical activities, but we anticipate recovering that at some point in the future as we get better visibility into the COVID cases in the different communities. Our teams have done an incredible job, as I mentioned in my comments. Our physicians have supported our teams incredibly well, and then our corporate and other teams have made capabilities available to our institutions, allowing us to respond very appropriately. So I'm really pleased with our outcomes.

And we do believe that we're going to have to manage through COVID again. It's not something that's going to go away necessarily. But our ability to scale up, scale down, scale up, I think, has now been proven. We've gained greater confidence in our ability to run our business, and at the same time, respond to surges.

And so the execution and the agility that our facilities and our teams have showed over this period of time helps us in developing learnings that we will be able to advance as we go forward on into this year.

Mark Kimbrough -- Vice President of Investor Relations

All right. Thank you, Justin. Next question, please.

Operator

Your next question comes from the line of Gary Taylor of JP Morgan. Your line is open.

Gary Taylor -- J.P. Morgan -- Analyst

Hi, thank you. Really impressive expense management in the quarter. It's really commendable. I guess, I just want to follow up a little bit and understand what you're saying.

I think I understand it. So if we look at this improving trajectory of revenue and volume through the quarter and we get to July, you're saying inpatient census is up, but I guess, COVID is fueling some of that. And surgical volume is down. Is that really -- I mean, just really happening sort of in Texas and Florida and not in the hotspots? Is there diversity of that experience even in those states? And then, when we look at the rest of the portfolio, though, that perhaps isn't being as hit by the resurgence as much.

Are you still generally seeing an improving trajectory out of June into July? So I guess, what I'm trying to get at is there any sort of pent-up demand that's now diminishing? Or is it really just the virus that's causing some of the surgical activity to slow down in some of those hotspots?

Sam Hazen -- Chief Executive Officer

All right. Thanks, Gary. Well, we have not restricted elective procedures or surgeries in markets where we don't have a need to respond to COVID. So obviously, in Texas, it started out in Houston in the Valley, and those were the first markets where we implemented our elective procedure decisions.

Then as it expanded to San Antonio, we replicated that in that market. So it's sequenced based upon the circumstances, and it will unsequence, if you will, based upon the circumstances. So in Dallas-Fort Worth, for example, which is not as significantly impacted by COVID, we have started to relax some of our procedure requirements and restrictions in order to deal with the circumstances in those communities. So we're going to see some natural ebb and flow in Florida similarly.

And then, if we were to see it somewhere else, we would use those experiences that we learned in Texas and Miami, as an example, to manage the situation. And this is what we're required to do with respect to our responsibilities as community infrastructure. We take it seriously, and we think we've been able to prove to ourselves and prove to the community that we can respond effectively to the needs of our patients whenever COVID does surface at a level that's much greater than what we were seeing in April and May. And we had some of this activity in June in some markets where we had COVID surge going on.

It wasn't as high profiled as what it was in Texas and Florida. Again, we were managing through that within our portfolio. Similarly, and learning from that, Gary, and putting those learnings into our experiences now, and I'm confident that we will continue to learn and gain greater capabilities in managing the volume requirements and the ups and downs of this particular pandemic.

Mark Kimbrough -- Vice President of Investor Relations

All right. Thanks, Gary. Next question, please.

Operator

Your next question comes from the line of A.J. Rice with Credit Suisse. Your line is open.

A.J. Rice -- Credit Suisse -- Analyst

Hi, everybody. Yes, great job on the crazy quarter. Maybe just ask about the backlog or the pent-up demand. I don't know whether there's any way that you're able to assess maybe through your doctor practices what that looks like.

Is that something that's going to go through the rest of the year? Could that spill over into next year? And there's business discussion about rebuilding a new pipeline, not just working through the backlog. Can you talk about your sense of people doing the primary care to build the case backlog for surgeries in orthopedics and all that stuff? And then, if I could just slip one other in. Bill mentioned the capex decline, can you comment on where you're pulling back on capex since you reassumed that you'll have to do more next year as a result of pulling back this year? Or are these things, it will permanently go away? Thanks.

Mark Kimbrough -- Vice President of Investor Relations

Thanks, A.J.

Sam Hazen -- Chief Executive Officer

OK, A.J., it's Sam. Thank you for the questions. I will give you some I will give you some observations. It's really difficult for us to pinpoint precisely what's going on in these circumstances, but we believe that approximately 40% to 50% of the deferred cases during the six- to seven-week period where most of our company was restricted on what we can do has been recaptured.

And by recaptured, I mean, either done or scheduled. So the other 40% to 50% that hasn't been recaptured, we don't have visibility into the timing of that yet. Our physicians continue to build back their practices, just as we're building back our business in a way that should hopefully recapture some of that gap that I just mentioned, but we don't have great visibility into that as of yet. What I will tell you also is that our ambulatory surgery centers were slower in their ramp-up because they were at a complete stop versus our hospitals which we're continuing to run during the pandemic period, and so they have ramped a little bit slower, as Bill alluded to in his comments.

What we saw within our surgery were procedures, orthopedic, spine, general surgery recovered quicker and stronger. We also saw a slower recovery in our GI procedures in certain diagnostic categories which started to ramp significantly at the end of June, which gives us a belief that, downstream, those diagnostic patients and encounters will ultimately require some level of therapy, whether it's surgery or something else. So we have some insights into it. We believe we'll need through the third quarter, probably through the fourth quarter to have a better sense of what the full recapture was of the cases that were, in fact, deferred.

In cardiology, components of our cardiology business recovered really well, mainly electrophysiology and the procedures in that particular category. So we had a mixed bag of events in the second quarter, and there are some indications of decent recovery in certain service lines, still more to come in others. And we will continue to monitor and try to gain insights from -- within our physician practices whether they're affiliated or employed and within the different markets that we think are more advanced in their recovery period than others and let that inform some of our observations further as we go into this next quarter.

Mark Kimbrough -- Vice President of Investor Relations

Bill, do you want to talk about the capital?

Bill Rutherford -- Chief Financial Officer

Yes. A.J., this is Bill. We think it was prudent at the time to reduce our capital spending, as we talked about last quarter and updated on this quarter. Most of those projects were either deferral or slowing down some activity that was in the pipeline, as well as some deferral of our IT capital.

We don't believe any of those physicians have compromised the strategic or growth initiative for us at this point. Actually, during the quarter, we turned on a couple of projects that we felt there were compelling opportunities out there. As far as next year, we'll have to see what the marketplace and the environment is. I don't think just because we deferred these that we'll have to substantially increase over what we ordinarily would have planned, but we'll continue to evaluate that as we through these different cycles.

Mark Kimbrough -- Vice President of Investor Relations

Thank you, A.J. OK.

Operator

Your next question comes from the line of Pito Chickering of Deutsche Bank. Your line is open.

Pito Chickering -- Deutsche Bank -- Analyst

Good morning, guys. Thanks for taking my questions and excellent job on a very challenging environment to the whole team over at HCA. So the question here is actually on the cost control side that you walked us through the revenue ramp throughout the quarter. But can you walk us through the sustainability of the cost control leverage that you put in place in April and March? And as the June positive revenues continue into July in the third quarter, how should we think about the cost controls you put in place?

Bill Rutherford -- Chief Financial Officer

Yes. Pito, this is Bill. Let me give a start to that. I think generally speaking, we can hold much of the cost controls that we put in place.

As we said, most of those were around adjusting some of our discretionary spending, as well as some of the variable costs. I think as Sam mentioned in his comments, we do know this recent COVID surge, we're having to make sure we have the appropriate labor to serve that surge that may result in some increased use of either contract or premium labor. But I think, as a whole, our teams have done a nice job. We continue to have opportunities to continue to look at other discretionary spending that we have.

So I think we've got a little bit of a track record of being able to manage to the environment, manage to the revenue that we have. We're very pleased with the results, and we're just going to have to see how the volume returns and what are the variable costs that we're going to need to support that. But we feel, for the most part, we can hold much of the expense adjustments that we made during the quarter.

Mark Kimbrough -- Vice President of Investor Relations

Thank you, Pito.

Operator

Your next question comes from the line of Matthew Gillmor of Baird. Your line is open.

Matthew Gillmor -- Robert W. Baird and Company -- Analyst

Hey, thanks for the question. I was hoping I could get an update on the potential for some M&A in the future. I know the industry is, obviously, working very collaboratively right now. But are you seeing any health systems that will be attractive partners for HCA struggling at all? And do you think you'll have more shots on goal from an M&A standpoint as you look out over the next one or two years?

Sam Hazen -- Chief Executive Officer

Thank you, Matt. This is Sam, Matt. I don't know that we have any insights yet, market insights into competitor issues or opportunities that might exist. I think everybody is scrambling in many markets to deal with COVID-19 possibilities appropriately, and the likelihood of any strategic decisions being made during this particular period in time, I think, is probably not that high.

We will continue to explore. We have a very robust pipeline for outpatient facility development and/or acquisitions that we're very excited about, and they're complementing of our existing networks. And we'll continue to look for adjacencies within that platform as. It relates to new market opportunities and so forth, I will just have to be, I think, aware and open to those but very conservative and appropriate in how we think about them and capital allocation, as Bill just alluded to, on our planning.

I don't know, though, at this point in time that we're going to see anything in the short run. I think it's going to take systems a while to get through this period and then start to determine what their appropriate steps are. But as we've done in the past, we have been opportunistic with respect to certain acquisitions, and we will continue to maintain that philosophy and appropriately move forward.

Mark Kimbrough -- Vice President of Investor Relations

All right. Thank you, Matt.

Matthew Gillmor -- Robert W. Baird and Company -- Analyst

Fair enough. Thank you.

Mark Kimbrough -- Vice President of Investor Relations

Next question, please.

Operator

Your next question comes from the line of Whit Mayo of UBS. Your line is open.

Whit Mayo -- UBS -- Analyst

Hey, thanks. Good morning. Maybe it's too early to tell, but any color around payer mix? I mean, any help on any internally developed framework to think about what the impact could be on HCA going forward? I mean, I know you've had a lot of time to address this and just wanted to get an updated view because my sense is that you're probably not seeing any meaningful change in, I guess, call it, your core payer mix now. And maybe just an update on your self-pay and balance after reserve, just where those are.

Bill Rutherford -- Chief Financial Officer

Yeah, Whit, this is Bill. As we mentioned in the payer mix, we did see some favorable in the payer mix as our commercial declines were a little less than our Medicare declines, which makes sense that the Medicare population may take a little bit longer time to return to a healthcare facility. Our uninsured volumes remain consistent with our overall volumes that we haven't seen any material kind of differential with our self-pay volume. Going forward, that's, obviously, an area that we're paying attention to.

We're doing a lot of study market by market to track various factors, whether that be unemployment or coverage. I think it is too early to be able to predict how that may unfold. But clearly, some of those factors will contribute to some of the uncertainty as we face the future and factor into some of our decisions. But we haven't seen it play out right now.

But as we go forward, it's an area that we continue to monitor, and we have some data that we're trying to track to give us some insight as we go into our 2021 planning cycle.

Mark Kimbrough -- Vice President of Investor Relations

All right, Whit. Thank you. Next question, please.

Operator

Your next question comes from the line of Steven Valiquette of Barclays. Your line is open.

Steven Valiquette -- Barclays -- Analyst

Great. Thanks. So generally speaking, I think most investors have been thinking about 2Q '20 likely being a trough for the hospital industry profitability then sequential improvements in 3Q and 4Q. And I guess, my question is if we just ignore the stimulus money and look at your strong $1.85 billion of operational EBITDA generated in 2Q, just operationally, should the investment community generally assume that operational EBITDA will continue to improve sequentially, at least in 3Q, from the $1.85 billion base, the way you see things right now, despite the fluid situations in Florida and Texas? Or is it too hard to make that call right now, just on the quarterly cadence?

Bill Rutherford -- Chief Financial Officer

Yes. Steven, this is Bill. Let me try. I mean, I think the reality is there are still many unknowns relative to the duration and impact this pandemic will have.

It's one of the reasons we cannot update our guidance at this point. It's unclear the longer-term macroeconomic impact, how this might change the overall landscape, including patient behavior, the economy, employment and coverage and the like. So these are kind of somewhat unprecedented times for us, so it's really hard to really project on a quarter-by-quarter basis what we might see. What we do know is that we've demonstrated, and I think as we demonstrate in this quarter, we have plans in place to respond, I think, to a range of scenarios that might unfold.

And we have different stages of management actions based on how either the volume returns or what the mix may be and the like. So we'll continue to assess the market, let you know what we are seeing as we go through the year. But right now, we're just unable to convert that to any type of financial guidance going forward, and we're just going to have to wait to see how the marketplace unfolds.

Steven Valiquette -- Barclays -- Analyst

OK. Appreciate the color. Thank you.

Mark Kimbrough -- Vice President of Investor Relations

All right. Thank you, Steven. Next question, please.

Operator

Your next question comes from the line of Kevin Fischbeck of Bank of America. Your line is open.

Mark Kimbrough -- Vice President of Investor Relations

Hey, Kevin.

Kevin Fischbeck -- Bank of America Merrill Lynch -- Analyst

Great. Thanks. I guess, just trying to go back to the pace and timing of volumes, I mean, you guys, obviously, operate in a lot of different markets across the country. I don't know if you have any experience about markets that maybe got hit a little bit earlier from COVID and have since rebounded and whether the elective procedures coming back are coming back a lot quicker in those markets or if it's more balanced.

I guess, in the past, you've given some data about procedures by the different regions that you guys -- or divisions that you guys have. Maybe color there on maybe as far as June goes, how many of those 14 are kind of at or above where they were because it sounds like June overall is up, but what percent of those regions are seeing above-average volumes?

Mark Kimbrough -- Vice President of Investor Relations

Great. Kevin, thank you. Sam, do you want?

Sam Hazen -- Chief Executive Officer

So here's how we looked at the recovery. We baselined everything off of April, and we looked at May and June and highlighted within our portfolio what the revenue growth was in each of those months vis-à-vis April. And for the most part, we had remarkably consistent performance across the divisions with the exception of a couple of spots. Those two spots were out west in California, primarily; and then in Miami, secondarily.

And that was because of releasing the restrictions a little bit slower in parts of California than Texas and Tennessee and places like that, as an example. And then, Miami was dealing with COVID in a totally different scenario, and their restrictions were released a little bit differently. But within those two brackets, most of our divisions ramped reasonably consistent as it relates to their revenue growth over April, and so that's how we judged it. Again, it's very difficult for us to get very specific observations from one category to the other within procedures and so forth.

But looking at the revenue recovery as the better metric, we were able to see remarkable consistency across the rest of the company with respect to gains over April.

Mark Kimbrough -- Vice President of Investor Relations

Kevin, Thank you for the question. And we're ready for another one.

Operator

Your next question comes from the line of Frank Morgan of RBC Capital Markets. Your line is open.

Frank Morgan -- RBC Capital Markets -- Analyst

Good morning. It sounds like in your comments that you really are more prepared as an enterprise for ebbs and flows in COVID volumes. And I'm just curious, do you think that plays out with doctors, with physicians, as well as patients? And that over time, if we do have another flare-up in the fall that -- I mean, basically, we all become more desensitized to this. We figure out how to operate, and the whipsaws that we see become less noticeable in the future.

And I guess, related to that, you did talk about on this current surge, an increase in things like premium labor, contracted labor and the likes. Maybe just any color you can tell us about general profitability of these COVID patients. Is it actually a profitable business when you bring it in? And then last, just any D.C. perspective.

Bill made some comments about the funding you received, and you've got lost revenue and higher costs. Any thoughts around additional relief funding for the hospital industry?

Mark Kimbrough -- Vice President of Investor Relations

All right, Frank. I've got three questions, all right?

Sam Hazen -- Chief Executive Officer

Yes. So Frank, let me speak to the ability to respond, downsize, upsize and respond again. I think we've proven to ourselves, as I mentioned, an ability to manage through that operationally as a facility and as a company. I also think government -- many state governments have learned how to respond and to dial up, dial down maybe some of their policies.

I think, this is my judgment only, that individuals understand how to dial up, dial down their social activities in a way that is responsive to what's going on in their communities as well. So I think all of this is creating a bit of muscle memory, if you will, with respect to COVID-19. It's our belief that we're going to have to maintain that memory, use that memory again and be able to deal with the potential flare-ups that might occur until we have a vaccine or a different kind of therapeutic remedy that would allow for less COVID activity in our communities. So I think it's not just us.

It's policies, it's business, it's individuals, all taking advantage of these learnings and applying them to the situations that we believe will still exist in the future until there's some vaccine. So Bill?

Bill Rutherford -- Chief Financial Officer

Yeah, Frank, I think it's too early to talk about the profitability of COVID patients. What we do know early on is that our COVID patients that we saw did have generally a higher acuity than our typical medical patient, just given a longer length of stay, a higher proportion in intensive care units. And there were some add-on payments by Medicare, as we know, but too early to really convert that to profitability. Our focus is really making sure that we've got all the resources to be able to care for those patients.

Mark Kimbrough -- Vice President of Investor Relations

All right, Frank. Thank you much. Ian, next question, please.

Operator

Your next question comes from the line of Ralph Giacobbe of Citi. Your line is open.

Ralph Giacobbe -- Citi -- Analyst

Thanks. Good morning. First, just wanted to clarify. You said June inpatient admission was about 1%, and July inpatient was running ahead.

Or was that commentary just on Texas? And then, more specifically on the ER volume, I know down 33%. What are some of the initiatives you're working on to get maybe people more comfortable to come in, if any? And then, you've been talking for a while on access points and increasing those access points. Where are you with that? And how does the backdrop sort of change or accelerate that? Thanks.

Sam Hazen -- Chief Executive Officer

Right, right. Thank you, Ralph. So what I mentioned -- this is Sam. What I mentioned on July was that our inpatient census was up over June.

We haven't finished the month yet, so it's difficult to say exactly where admissions are going to be. With respect to emergency room activity, again, we saw sequential improvement in the rate of decline in our emergency room business in the second quarter with June being down maybe half of what it was down or third, less, what was it, 15% down, yes, versus roughly 4% down, I think, it was in April. So we saw significant improvement, if you will, from the rate of decline. What we also saw inside of our emergency room business was greater acuity.

We had, similar to our inpatient business, greater acuity in our ER patients who visited our facilities. And that yielded revenue per ER visit that was slightly above our expectations. So the business that we're losing is the lower acute business, which you would expect. We saw within our freestanding emergency room slightly quicker ramp-up than we did our hospital-based ERs.

Again, some of that could be due to patient concern with respect to COVID. We have a very aggressive campaign, both operationally from a patient safety standpoint, as well as a communication standpoint, with our patients on demonstrating to them the safe environment that they deserve when they come to one of our facilities. As it relates to developing our outpatient platform in order to support our hospitals, we continue on that pathway. We think it's an important part of taking the care experience to the patient, creating a more efficient, a better price point for them.

And we will continue to invest in that platform. We currently have a number of our outpatient facilities that are reopening as a result of the COVID pandemic closures that took place. So each week, we opened more of what we had previously closed. We're not up to 100% reopening of our freestanding ERs in some markets or urgent care centers in other markets.

On top of that will be telemedicine. We have, as I mentioned in my comments, developed rather quickly a telemedicine capability, which is critically important, we think, to furthering our access strategies for our patient and creating convenience for them and efficiency for our physicians. So we will continue to invest in that and build capabilities that supports that as a wraparound platform. So I'm very encouraged by what we have done.

I'm encouraged by what we're seeing in the recovery in these outpatient activities. And as we move forward, anticipate that we will continue to develop these wraparound capabilities that support our hospitals in a way that make it easy for our patients. And then, if they need deeper care, they can get more sophisticated and deeper care inside of our hospitals.

Mark Kimbrough -- Vice President of Investor Relations

All right. Thanks Sam. Thanks, Ralph. Next question, please.

Operator

Your next question comes from the line of John Ransom of Raymond James. Your line is open.

John Ransom -- Raymond James -- Analyst

Good morning. I'll add my congratulations. That's a remarkable job in an unprecedented situation. I'm curious, as we look at July and you've got at least temporarily some inpatient capacity constraints in Texas and Florida, have you been able to -- and through flexing capacity or moving things to outpatient, have you been able to move a material amount of maybe what would have been an inpatient elective a year ago into a different setting? Or does it kind of looked like it did before?

Sam Hazen -- Chief Executive Officer

Thanks, John. Well, I think -- this is Sam again. What we have done with capacity management to deal with COVID is quite remarkable. We've developed technology capabilities to give us real-time insights into our patient population into every bed in the facility at any point in time also giving us an indication of their clinical condition, allowing us to think about and work with their physicians to possibly place them in a different setting.

That has allowed us to increase the throughput in many respects versus what we were able to do in the past. So that's an outgrowth of what happened during COVID that we think is going to create value for our patients, create better use of our assets in the future and create more value for our payer partners in the future as well. The other thing that we've done during COVID is we have been able to, what we call, level load patients across our network. And by that, I mean, getting patients into the right facility even when we know we're going to have a pressure point at a particular facility because of the community issues that are going on.

So moving patients to where we had staffing or moving patients to where we had beds was another piece of capability that I think we advanced. We do that all the time with hurricanes,as we deal with hurricanes, but we took our hurricane learnings and applied that to COVID situations where we had stress. The area where we've seen slight acceleration of inpatient to outpatient over what we saw pre-COVID is in some of our surgical cases, mainly orthopedic total joint, where there was a natural progression of inpatient to outpatient. It's slightly higher post-COVID than it was pre-COVID.

It's not significantly higher, but it is higher. And is that something that's going to continue? We believe that it will be there. We anticipated in our planning, our multiyear planning that orthopedic total joints would continue to migrate to more outpatient activity, but we're built for that. We collaborate with our physicians on making sure that we're dealing with the patient in the proper setting.

We have an ambulatory surgery center platform that if that's the best setting, they can go to that. So we have prepared ourselves for this migration. Outside of total joints, I wouldn't submit that there's anything material that's taken place that's been part of our overall capacity management. It needs to be clinically driven, not capacity driven.

And as long as it's clinically effective for the patient, then we'll support that and hopefully accomplish that in a way that's productive for the capacity, and at the same time, appropriate for the patient.

Mark Kimbrough -- Vice President of Investor Relations

Thank you, John.

John Ransom -- Raymond James -- Analyst

Great. Thank you.

Mark Kimbrough -- Vice President of Investor Relations

And we've got time for two more questions.

Operator

Your next question comes from the line of Joshua Raskin of Nephron Research. Your line is open.

Joshua Raskin -- Nephron Research -- Analyst

Hi. Thanks and appreciate all the work you did. So mine's on the CARES Act funding, you received, I think, a total of $1.4 billion, plus an additional $300 million after the quarter. You recognized $822 million.

And I understand the difference between the general distribution of $920 million and then the more targeted, what seems like $750 million or so. So I guess, the question is do you think you're going to be able to actually recognize even that incremental $100 million or $98 million of the general distribution or any of the targeted distributions? Or you've just not seen that level of impact to either volumes or costs?

Bill Rutherford -- Chief Financial Officer

Yeah, Josh, this is Bill. Let me try to highlight that. As you might know, the terms and conditions and the general guidance for these funds continue to evolve and update. And for the most part, you have a 90-day or longer period to go through and analysis and attestation process.

And we're in the middle of our analysis and validation procedures for those funds right now. So it's really too early to talk about when and how much we might recognize in the future. We continue to monitor the guidance that comes out from various government agencies, and we continue to do our analysis. For the targeted funds, we have until mid -- until late third quarter and even July in the fourth quarter.

So we'll continue our analysis and go forward, and we'll discuss with you what that results when we go through future periods.

Mark Kimbrough -- Vice President of Investor Relations

Thank you, Josh. And we're ready for our last question.

Operator

Your last question comes from the line of Scott Fidel of Stephens. Your line is open.

Scott Fidel -- Stephens Inc. -- Analyst

Hi, thanks. And thanks for fitting me in here. I just had one other CARES question as well and just relating to the Medicare advance payment that you and the others have received in the industry. And I know those payments are supposed to get started to get paid back in August and over the course of eight months.

Obviously, still a lot of virus impact, and it seems like a lot of other hospitals in the industry are facing a lot of financial pressure still. So just interested if you're hearing any or you have any line of discussions with CMS in terms of them maybe looking to delay in terms of when facilities are required to start repaying those Medicare advance funding that was paid out in 2Q? Thanks.

Bill Rutherford -- Chief Financial Officer

Yeah, Scott, this is Bill. I know there's been some discussion, but I don't have any insight into how those have progressed. As you probably know, it's scheduled to be repaid and offset against Medicare claims in the future beginning in August, so we'll just have to see what that cadence goes. But I know there's been some discussion.

We've read about some potential altering to how those funds and what the time period may be, but I don't have any insight on what ultimately may come from those discussions.

Mark Kimbrough -- Vice President of Investor Relations

Scott, thank you for the question. Appreciate it. All right. Listen, I want to thank everybody who joined us today and participated on the call.

As always, we're here to answer any of your questions. And so take care, have a good day, and be safe. Thank you.

Operator

[Operator signoff]

Duration: 60 minutes

Call participants:

Mark Kimbrough -- Vice President of Investor Relations

Sam Hazen -- Chief Executive Officer

Bill Rutherford -- Chief Financial Officer

Justin Lake -- Wolfe Research -- Analyst

Gary Taylor -- J.P. Morgan -- Analyst

A.J. Rice -- Credit Suisse -- Analyst

Pito Chickering -- Deutsche Bank -- Analyst

Matthew Gillmor -- Robert W. Baird and Company -- Analyst

Whit Mayo -- UBS -- Analyst

Steven Valiquette -- Barclays -- Analyst

Kevin Fischbeck -- Bank of America Merrill Lynch -- Analyst

Frank Morgan -- RBC Capital Markets -- Analyst

Ralph Giacobbe -- Citi -- Analyst

John Ransom -- Raymond James -- Analyst

Joshua Raskin -- Nephron Research -- Analyst

Scott Fidel -- Stephens Inc. -- Analyst

More HCA analysis

All earnings call transcripts